

2023 Current Fiscal Year Report: President's Cancer Panel

Report Run Date: 03/28/2024 10:03:28 AM

1. Department or Agency

Department of Health and Human
Services

2. Fiscal Year

2023

3. Committee or Subcommittee

President's Cancer Panel

3b. GSA Committee

No.

1001

4. Is this New During Fiscal Year?

5. Current Charter

6. Expected Renewal Date

7. Expected Term Date

No 05/31/2022 05/31/2024

8a. Was Terminated During Fiscal Year?

No

8b. Specific Termination Authority

8c. Actual Term Date

9. Agency Recommendation for Next Fiscal Year

Continue

10a. Legislation Req to Terminate?

Not Applicable

10b. Legislation Pending?

Not Applicable

11. Establishment Authority

Statutory (Congress Created)

12. Specific Establishment Authority

42 U.S.C. 285a-4

13. Effective Date

11/20/1985

14. Committee Type

Continuing

14c. Presidential?

Yes

15. Description of Committee

National Policy Issue Advisory Board

16a. Total Number of Reports

No Reports for
this Fiscal Year

17a. Open

1

17b. Closed

0

17c. Partially Closed

0

Other Activities

0

17d. Total

1

Meetings and Dates

Purpose

Program Advisory and/or Policy

Start

09/07/2023

End

- 09/07/2023

Number of Committee Meetings Listed: 1

Current FY

Next FY

18a(1). Personnel		
Pmts to Non-Federal Members	\$7,706.00	\$29,527.00
18a(2). Personnel		
Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel		
Pmts to Federal Staff	\$309,773.00	\$325,881.00
18a(4). Personnel		
Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per		
Diem to Non-Federal Members	\$2,500.00	\$10,091.00
18b(2). Travel and Per		
Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per		
Diem to Federal Staff	\$0.00	\$4,366.00
18b(4). Travel and Per		
Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)		
	\$356,393.00	\$359,957.00
18d. Total	\$676,372.00	\$729,822.00
19. Federal Staff		
Support Years (FTE)	2.00	2.00

20a. How does the Committee accomplish its purpose?

The committee is composed of three members who provide advice and recommendations to the President of the United States in the areas of policy, health care, research, and information dissemination. The Panel monitors the development and execution of the activities of the National Cancer Program. Any delays or blockages in rapid execution of the Program are

immediately brought to the attention of the President. The Panel conducts meetings throughout the country that serve as a forum for the scientific community and for the public. Based on expert testimony presented and discussions occurring at these meetings, the Panel makes recommendations, some of which have affected the initiation of new NCI programs and the implementation of existing priorities. In FY23, a meeting was held on September 7, 2023 to gather information from stakeholders regarding activities addressing the goals the National Cancer Plan. A series of meetings are planned for FY24 regarding reducing cancer care inequities through leveraging technology to enhance patient navigation. This topic aligns with and supports two of the eight National Cancer Plan goals: to Eliminate Inequities and to Deliver Optimal Care. The President's Cancer Panel will prospectively assess the needs related to these goals, focusing on gaps and opportunities related to the use of technology to support cancer patient navigation. The series of meetings will focus on opportunities for enhancing patient navigation; technology opportunities for patient navigation; and policy considerations at the intersection of technology and patient navigation.

20b. How does the Committee balance its membership?

The President's Cancer Panel consists of three persons appointed by the President, who by virtue of their training, experience and background, are exceptionally qualified to appraise the National Cancer Program. It is mandated that at least two of the members of the Panel will be distinguished scientists or physicians.

20c. How frequent and relevant are the

Committee Meetings?

Meetings are generally held not less than four times each fiscal year at the call of the Chair. Due to the appointment of new members, there was only one meeting held in FY23. A meeting was held on September 7, 2023 to gather information from stakeholders regarding activities addressing the goals the National Cancer Plan.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The President's Cancer Panel was established by law, and the chairman submits to the President, the Secretary, and the Congress an annual evaluation of the National Cancer Program and suggestions for improvements. The Panel also submits such other reports as the White House requests. The quality, scope, and balance of advice from this Panel cannot be obtained from NIH staff or from other established sources because the membership of the Panel is constituted to meet the specific requirements of its mandated mission to appraise the National Cancer Program.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Max Number of Members Total: The Charter allows the Committee to have 3 authorized members, which equals to the total of 3 of members. Members Rotating Off/On-Boarding: Three members rotated off (Mr. Robert Ingram, Dr. Edith Mitchell, and Dr. John Williams) and three members on-boarded (Drs. Mitchel Berger, Carol Brown, and Elizabeth Jaffee). That is why the Charter states 3 members, but this ACR lists

6. Members: The terms for Mr. Robert Ingram, Dr. Edith Mitchell, and Dr. John Williams changed due to the appointment of new PCP members. As such, their term of service end dates are different than what was reported on the FY22 ACR.

Meetings: Due to the appointment of new PCP members, only one meeting was held in FY23.

Reports: This committee did not produce any public reports. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

Designated Federal Officer

MAUREEN R. JOHNSON SPECIAL ASSISTANT
TO THE DIRECTOR

Committee Members	Start	End	Occupation	Member Designation
BERGER, MITCHEL	01/17/2023	02/20/2026	BERTHOLD AND BELLE N. GUGGENHIME PROFESSOR, DIRECTOR, BRAIN TUMOR RESEARCH CENTER, SCHOOL OF MEDICINE, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Special Government Employee (SGE) Member
			SENIOR VICE PRESIDENT AND CHIEF HEALTH EQUITY OFFICER, NICHOLLS-BIONDI CHAIR FOR HEALTH EQUITY, MEMORIAL SLOAN KETTERING CANCER CENTER	Special Government Employee (SGE) Member
			GENERAL PARTNER; HATTERAS VENTURE PARTNERS	Special Government Employee (SGE) Member
BROWN, CAROL	01/17/2023	02/20/2024		
INGRAM, ROBERT	08/30/2020	01/16/2023		

JAFEE, ELIZABETH	01/29/2023	02/20/2025	THE DANA AND ALBERT "CUBBY" BROCCOLI PROFESSOR OF ONCOLOGY, DEPUTY DIRECTOR, SIDNEY KIMMEL CANCER CENTER AT JOHNS HOPKINS, CO-DIRECTOR. GASTROINTESTINAL CANCERS PROGRAM, JOHNS HOPKINS UNIVERSITY CLINICAL PROFESSOR OF MEDICINE AND MEDICAL ONCOLOGY, DEPARTMENT OF MEDICAL ONCOLOGY, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member
MITCHELL, EDITH	02/16/2020	01/16/2023	MEDICAL ONCOLOGY, DEPARTMENT OF MEDICAL ONCOLOGY, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member
WILLIAMS, JOHN	03/15/2020	01/16/2023	MEDICAL ONCOLOGY, DEPARTMENT OF MEDICAL ONCOLOGY, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member

Number of Committee Members Listed: 6

Narrative Description

NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. Annual identification and assessment of the issues facing the National Cancer Program contribute to the advancement of this mission and the development of the NIH strategic plan in regards to cancer. Over its approximately 40 year history, the Panel has engaged in active dialogue with all participants in the National Cancer Program [the Program] in an effort to assess the progress and coordination of the Program. The Panel has generally held four or more meetings in each series to gather information and to stimulate discussion among prominent scientists, clinicians, academia, business, industry and the government. Recent topics

have included closing gaps in cancer screening by connecting people, communities, and systems to improve equity and access; how to increase the uptake of the human papillomavirus (HPV) vaccine; the potential for connected health strategies and technologies to engage and activate individuals and patients, with the ultimate goal of improving cancer-related outcomes; ensuring patients' access to high-value cancer care; and accessing and improving cancer screening drugs. The current topic being explored is reducing cancer care inequities by leveraging technology to enhance patient navigation. As a link between the President and the public on cancer issues, the Panel provides information that informs cancer policy at the Executive level through its mandate to assess the efficacy of the National Cancer Program. The meetings of the Panel present a unique opportunity to identify and bring together the vast research, health care and manpower resources of this Nation by eliciting public testimony in assessment of the National Cancer Program. The PCP meetings provide the President with the means to identify both the strengths and the weaknesses of the National Cancer Program and the opportunity to seek out needed adjustments. The Panel fills a critical need as the sometimes costly screening, treatment, and technological advances made possible through cancer research must be successfully and equitably applied throughout the country to alleviate suffering and death caused by cancer.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

Improvements to health or safety	<input checked="" type="checkbox"/>
Trust in government	<input checked="" type="checkbox"/>
Major policy changes	<input checked="" type="checkbox"/>
Advance in scientific research	<input checked="" type="checkbox"/>
Effective grant making	<input type="checkbox"/>
Improved service delivery	<input checked="" type="checkbox"/>
Increased customer satisfaction	<input checked="" type="checkbox"/>
Implementation of laws or regulatory requirements	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

Outcome Comments

The PCP, because it is charged under the Cancer Act to assess the program, has indicated that it has responsibilities in all areas of the cancer program which includes the above.

What are the cost savings associated with this committee?

Checked if Applies

None	<input type="checkbox"/>
Unable to Determine	<input checked="" type="checkbox"/>
Under \$100,000	<input type="checkbox"/>
\$100,000 - \$500,000	<input type="checkbox"/>
\$500,001 - \$1,000,000	<input type="checkbox"/>
\$1,000,001 - \$5,000,000	<input type="checkbox"/>
\$5,000,001 - \$10,000,000	<input type="checkbox"/>
Over \$10,000,000	<input type="checkbox"/>
Cost Savings Other	<input type="checkbox"/>

Cost Savings Comments

NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

204

Number of Recommendations Comments

In FY 2023 the committee unanimously approved the formation of a Working Group on Addressing Inequities in Cancer Care through Innovative Navigation Models.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

0%

% of Recommendations Fully Implemented Comments

Due to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

0%

% of Recommendations Partially Implemented Comments

Due to the large breadth and complexity of the recommendations made by this committee, NCI staff is unable to determine which recommendations have been fully or partially implemented solely in response to this committee's activities.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☒ No ☐ Not Applicable ☐

Agency Feedback Comments

Information is provided to the public at each meeting. The public can view information related to the Committee through the committee's official website.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

N/A

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

N/A

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
-------------	-------------------------------------

Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the PCP can be found at the President's Cancer Panel website at <https://prescancerpanel.cancer.gov>. Findings are also communicated through mailings and in person briefings.